BI Asset Management Fondsmaeglerselskab A S Has $15.04 Million Holdings in IDEXX Laboratories, Inc. $IDXX

BI Asset Management Fondsmaeglerselskab A S cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.2% in the first quarter, HoldingsChannel reports. The firm owned 26,765 shares of the company’s stock after selling 3,381 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in IDEXX Laboratories were worth $15,039,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of IDXX. Elyxium Wealth LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at about $3,666,459,000. State Street Corp lifted its position in shares of IDEXX Laboratories by 4.0% in the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after buying an additional 138,956 shares during the last quarter. J. Stern & Co. LLP boosted its stake in shares of IDEXX Laboratories by 23,694.7% during the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after acquiring an additional 2,642,200 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock worth $1,749,380,000 after acquiring an additional 86,263 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of IDEXX Laboratories by 13.8% during the 4th quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after acquiring an additional 181,955 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $562.09 on Friday. The company has a market cap of $44.34 billion, a P/E ratio of 41.39, a P/E/G ratio of 3.07 and a beta of 1.55. The stock’s 50-day moving average is $561.66 and its 200-day moving average is $620.91. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the company posted $2.91 earnings per share. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.